BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
| Revenue (TTM) | $2.65B |
| Gross Profit (TTM) | $2.03B |
| EBITDA | $-1.38B |
| Operating Margin | -807.00% |
| Return on Equity | -9.30% |
| Return on Assets | -5.41% |
| Revenue/Share (TTM) | $10.69 |
| Book Value | $79.26 |
| Price-to-Book | 1.22 |
| Price-to-Sales (TTM) | 8.31 |
| EV/Revenue | 2.696 |
| EV/EBITDA | 110.81 |
| Quarterly Earnings Growth (YoY) | -43.20% |
| Quarterly Revenue Growth (YoY) | -59.50% |
| Shares Outstanding | $251.20M |
| Float | $109.28M |
| % Insiders | 57.19% |
| % Institutions | 20.58% |
Volatility is currently expanding
Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.
Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.
BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements about its mRNA oncology programs gave shareholders an accurate picture.
MAINZ, Germany, October 13, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or “tenu-ra”).
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect.
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly.
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company's cancer vaccine pipeline over the valuation warning.
MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BNTX and any ticker you trade — then tracks every position and per-strategy win rate.
